6533b82cfe1ef96bd128ff3b
RESEARCH PRODUCT
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study.
Venerino PolettiDamiano D'ardesPaola SimeoneCristina MussiniGiustino ParrutiSandro MaccarellaLicia IacovielloGiulio G. StefaniniRoberta MussinelliVincenzo SangiovanniPaolo BonfantiRoberto VettorAndrea VianelloArturo MontineriRoberto CaudaElvira GrandoneMaria MazzitelliClaudia RavagliaMarialaura BonaccioGiulio MarescaFrancesco Di GennaroAlessandro MengozziAnna SabenaGian Battista DanziGiuseppe Di TanoEmanuela PasiIlaria RossiLucia CaianoLaura CarrozziFrancesco LandiFrancesca CrostaTommaso FilippiniFrancesco MenichettiPiergiuseppe AgostoniAndrea MadaroAntonio CascioCarlo SignorelliMichele SpinicciCarlo SanroccoEnrico Guido SpinoniMaria MussoAlessandra VergoriLorenzo MarraGiuseppe PattiLaura VoccianteMarco OlivieriFrancesca SantilliStefano PerliniClaudia ColombaSalinaro FrancescoMarianna MeschiariGabriella GuarnieriGiampiero D'offiziRiccardo MaragnaPaola Del GiacomoGiancarlo GiniKatleen De Gaetano DonatiAndrea AntinoriFilippo AucellaRaffaele De CaterinaLorenzo MenicantiGloria MaccagniAmedeo VeneziaChiara Dal PraCarlo Andrea PivatoWalter AgenoAntonella AgodiFrancesco CannataFrancesco PetriLuca AielloBiagio PincheraMarinella AstutoRaffaella SgarigliaGiovanni GuaraldiMarco VincetiMarco VincetiLaura ScorzoliniSamir Al MoghaziArmando LeoneGiovanni VeronesiArturo CicculloLeonardo GrisafiFrancesco CipolloneMassimo MapelliGreta BarbieriSilvia LamonicaRaffaele BrunoFilippo MinutoloAntonella CingolaniAlessandro GialluisiMarco RossatoAndrea RognoniMarianna RossiClaudia MarottaFranco MastroianniIlaria MyEnrico Maria TrecarichiAnna OdoneAlessandro BartoloniSimona CostanzoFrancesco CacciatoreIvan GentileMassimo RinaldiNausicaa BerselliFrancesco Maria FuscoAugusto Di CastelnuovoLorenzo Blandisubject
Malemedicine.medical_specialty030204 cardiovascular system & hematologyLower risklaw.inventionCOVID-19; Disease severity; Hydroxychloroquine; Inflammation; Mortality; Aged; Aged 80 and over; COVID-19; Female; Hospital Mortality; Humans; Hydroxychloroquine; Italy; Male; Middle Aged; Retrospective Studies; Treatment OutcomeCOVID-19; Disease severity; Hydroxychloroquine; Inflammation; Mortality03 medical and health sciences0302 clinical medicineRandomized controlled trialRetrospective StudielawInternal medicine80 and overInternal MedicinemedicineHumans030212 general & internal medicineHospital MortalityMortalityRisk factorDisease severityAgedRetrospective StudiesInflammationAged 80 and overbusiness.industryMortality rateCOVID-19HydroxychloroquineRetrospective cohort studyMiddle AgedCOVID-19 Drug TreatmentTreatment OutcomeItalyPropensity score matchingCommentaryObservational studyFemalebusinessHumanmedicine.drugHydroxychloroquinedescription
Abstract Background Hydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19. Objective We set-up a multicenter Italian collaboration to investigate the relationship between HCQ therapy and COVID-19 in-hospital mortality. Methods In a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers in Italy, from February 19, 2020 to May 23, 2020, with laboratory-confirmed SARS-CoV-2 infection, were analyzed. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received HCQ with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse probability for treatment weighting by propensity scores, with the addition of subgroup analyses. Results Out of 3,451 COVID-19 patients, 76.3% received HCQ. Death rates (per 1,000 person-days) for patients receiving or not HCQ were 8.9 and 15.7, respectively. After adjustment for propensity scores, we found 30% lower risk of death in patients receiving HCQ (HR=0.70; 95%CI: 0.59 to 0.84; E-value=1.67). Secondary analyses yielded similar results. The inverse association of HCQ with inpatient mortality was particularly evident in patients having elevated C-reactive protein at entry. Conclusions HCQ use was associated with a 30% lower risk of death in COVID-19 hospitalized patients. Within the limits of an observational study and awaiting results from randomized controlled trials, these data do not discourage the use of HCQ in inpatients with COVID-19.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-12-01 | European journal of internal medicine |